INCY - Incyte Corporation

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
99.00
+0.05 (+0.05%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close98.95
Open99.09
Bid0.00 x 0
Ask0.00 x 0
Day's Range98.28 - 100.26
52 Week Range96.60 - 153.15
Volume1,204,417
Avg. Volume1,829,263
Market Cap20.893B
Beta1.26
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Cramer's lightning round: Don't give up on Incyte
    CNBC Videos16 days ago

    Cramer's lightning round: Don't give up on Incyte

    Jim Cramer flew through his take on callers' favorite stocks, including what he called a "discouraging" pharmaceutical play.

  • Capital Cube2 days ago

    ETFs with exposure to Incyte Corp. : November 21, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Incyte Corp. Here are 5 ETFs with the largest exposure to INCY-US. Comparing the performance and risk of Incyte Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • MarketWatch2 days ago

    Six promising stocks to buy for the biotech rebound ahead

    A big selloff last week clears the way for buying opportunities, says Michael Brush.

  • Is Incyte Corporation’s (INCY) Liquidity As Good As Its Solvency?
    Simply Wall St.3 days ago

    Is Incyte Corporation’s (INCY) Liquidity As Good As Its Solvency?

    Investors looking for stocks with high market liquidity and little debt on the balance sheet should consider Incyte Corporation (NASDAQ:INCY). With a market valuation of USD $22.26B, INCY is aRead More...

  • See what the IHS Markit Score report has to say about Incyte Corp.
    Markit3 days ago

    See what the IHS Markit Score report has to say about Incyte Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding INCY totaled $862 million.

  • Incyte (INCY) Initiates Essential Thrombocythemia Trial
    Zacks7 days ago

    Incyte (INCY) Initiates Essential Thrombocythemia Trial

    Incyte (INCY) announced that the first patient has been treated in the essential thrombocythemia trial on ruxolitinib. A potential label expansion of the drug will boost sales.

  • See what the IHS Markit Score report has to say about Incyte Corp.
    Markit8 days ago

    See what the IHS Markit Score report has to say about Incyte Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding INCY is favorable, with net inflows of $16.07 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing.

  • See what the IHS Markit Score report has to say about Incyte Corp.
    Markit9 days ago

    See what the IHS Markit Score report has to say about Incyte Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Cramer's lightning round: Don't give up on Incyte
    CNBC16 days ago

    Cramer's lightning round: Don't give up on Incyte

    Jim Cramer flew through his take on callers' favorite stocks, including what he called a "discouraging" pharmaceutical play.

  • Benzinga17 days ago

    The Week Ahead: Earnings Season Continues, Several IPOs, Notable Conferences On The Docket

    Below is a list of notable corporate events for the week beginning November 6. Note, this list is not comprehensive and all dates are subject to change. Monday Notable Earnings CVS Health Corporation (NYSE: ...

  • November Top Growth Stocks
    Simply Wall St.19 days ago

    November Top Growth Stocks

    High-growth stocks that are financially stable are attractive for many reasons. They provide a strong upside to your portfolio, with less likelihood of downside risks compared to less financially robustRead More...

  • Incyte Tops Q3 Earnings & Sales, Extends AstraZeneca Deal
    Zacks22 days ago

    Incyte Tops Q3 Earnings & Sales, Extends AstraZeneca Deal

    Incyte Corporation (INCY) reported strong results in the third quarter on strong Jakafi sales and upped its guidance as well.

  • Thomson Reuters StreetEvents22 days ago

    Edited Transcript of INCY earnings conference call or presentation 31-Oct-17 2:00pm GMT

    Q3 2017 Incyte Corp Earnings Call

  • Biotech Stock Roundup: Celgene, Amgen, Gilead Hit by Q3 Results, Vertex Beats on All Fronts
    Zacks22 days ago

    Biotech Stock Roundup: Celgene, Amgen, Gilead Hit by Q3 Results, Vertex Beats on All Fronts

    It was all about earnings this week with major biotech companies like Gilead (GILD), Celgene and Amgen reporting third quarter results.

  • American City Business Journals23 days ago

    Incyte, AstraZeneca expand collaboration on potential lung cancer therapy

    Incyte Corp. is expanding its clinical collaboration with MedImmune, AstraZeneca's global biologics research and development arm. As part of the expanded agreement, the two companies will evaluate the effectiveness and safety of a combination therapy — featuring one product from each company — in treating patients with non-small cell lung cancer. The phase-III study of the treatment pairing Incyte's investigational enzyme inhibitor called epacadostat with AstraZeneca's Imfinzi human monoclonal antibody is expected to begin during the first half of next year.

  • TheStreet.com23 days ago

    Geron Shares Rise on Fast Track Designation -- Biotech Movers

    The FDA granted fast track designation to imetelstat as a potential treatment for adults with with transfusion-dependent anemia.

  • Associated Press23 days ago

    Incyte tops Street 3Q forecasts

    On a per-share basis, the Wilmington, Delaware-based company said it had profit of 17 cents. The results topped Wall Street expectations. The average estimate of 17 analysts surveyed by Zacks Investment ...

  • What Does Incyte Corporation’s (INCY) Share Price Indicate?
    Simply Wall St.23 days ago

    What Does Incyte Corporation’s (INCY) Share Price Indicate?

    Today we’re going to take a look at the well-established Incyte Corporation (NASDAQ:INCY). The company’s stock received a lot of attention from a substantial price movement on the NasdaqGS inRead More...

  • AstraZeneca plans new pivotal lung cancer trial with Incyte
    Reuters23 days ago

    AstraZeneca plans new pivotal lung cancer trial with Incyte

    AstraZeneca (AZN.L) is stepping up its bet on immunotherapy combination treatments to fight lung cancer by signing a deal with Incyte (INCY.O) under which the two companies will start a final-stage Phase III clinical trial next year. The study will test AstraZeneca's Imfinzi alongside Incyte's second-generation immunotherapy drug epacadostat, a so-called IDO inhibitor that also helps the immune system fight cancer.

  • Reuters23 days ago

    AstraZeneca plans new pivotal lung cancer trial with Incyte

    AstraZeneca is stepping up its bet on immunotherapy combination treatments to fight lung cancer by signing a deal with Incyte under which the two companies will start a final-stage Phase III clinical trial next year. The study will test AstraZeneca's Imfinzi alongside Incyte's second-generation immunotherapy drug epacadostat, a so-called IDO inhibitor that also helps the immune system fight cancer.

  • What's in the Cards for PFE, INCY and ACOR in Q3 Earnings?
    Zacks24 days ago

    What's in the Cards for PFE, INCY and ACOR in Q3 Earnings?

    The third-quarter reporting cycle is witnessing accelerating revenues and positive revisions trend for Q4. Let's see if some of the other leading players like Pfizer, Incyte and Acorda follow suit.

  • Zacks.com featured highlights: Incyte, Apache, Titan International, AMC Entertainment and Carbonite
    Zacks24 days ago

    Zacks.com featured highlights: Incyte, Apache, Titan International, AMC Entertainment and Carbonite

    Zacks.com featured highlights: Incyte, Apache, Titan International, AMC Entertainment and Carbonite

  • Get Rid of These 5 Toxic Stocks or Sell Short for Profit
    Zacks27 days ago

    Get Rid of These 5 Toxic Stocks or Sell Short for Profit

    Toxic stocks are vulnerable to outside shocks and are burdened with high amounts of debts. Also, the price of toxic stocks is inflated.

  • Why Incyte (INCY) Might Surprise This Earnings Season
    Zacks27 days ago

    Why Incyte (INCY) Might Surprise This Earnings Season

    Incyte (INCY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • American City Business Journals28 days ago

    Why this Rockville biotech's stock made a big jump this week

    Rockville-based biotech MacroGenics Inc. has inked an immunotherapy drug collaboration deal with Delaware-based Incyte Corp. that could be worth up to $900 million for the company. Under the deal announced Wednesday, MacroGenics (MGNX) will receive a $150 million upfront payment from Incyte (INCY). In exchange, Incyte gains development and commercialization rights to MacroGenics' anti-cancer drug candidate called MGA012.